Define the operating boundary
A useful definition names the triggering event, required inputs, governing source, accountable owner, decision or action, exception path, evidence retained, and downstream handoff. Buyers should adapt those elements to their own population, jurisdictions, policies, systems, and control model before writing requirements.
The most important distinction is between a label and an operational capability. A provider may document authorization status tracking while depending on customer-supplied policy, licensed content, third-party data, integration partners, manual review, or services. The demonstration should expose those dependencies rather than hiding them behind a completed interface.
What a demonstration should prove
- Begin with representative source records and a named policy, standard, or controlled rule.
- Show the normal path, an ambiguous case, missing data, an exception, an override, and a material source change.
- Identify who can change rules, who can approve or reject, and how accountability is preserved.
- Trace every output back to inputs, versions, timestamps, user actions, and governing evidence.
- Export the resulting record and reconcile it with downstream systems and retained obligations.
Authority and operating context
CMS-0057-F
The rule requires impacted payers to improve prior authorization decision timeframes and denial reasons, publish aggregated prior authorization metrics, and implement FHIR-based Prior Authorization and other interoperability APIs. The prior authorization API provisions addressed by the final rule exclude drugs. It changes prior authorization from a mainly plan-specific operational process into a federally time-bounded, reportable, and API-enabled workflow for impacted non-drug items and services. It also creates concrete buyer requirements for denial reasons, metrics lineage, and CRD, DTR, and PAS implementation.
HL7 Da Vinci PAS v2.2.1
PAS defines a FHIR R4 mechanism for submitting prior authorization requests, responses, status, updates, and supporting context in a way designed to map to applicable X12 transactions. It is one part of the Da Vinci burden-reduction workflow. PAS governs the request-and-response exchange after requirement discovery and documentation preparation. Claiming FHIR support without specifying PAS version, trading-partner workflow, X12 handling, and testing evidence is insufficient.
X12 278 Version 5010
The 278 implementation guide defines request and response transactions for admission certification, referrals, service certification, extensions, appeals, reservations, and cancellations between providers, utilization-management organizations, and intermediaries. Most current electronic medical-service prior authorization environments must account for the HIPAA transaction baseline even as CMS and Da Vinci workflows accelerate FHIR adoption. A credible architecture explains whether and where translation, enforcement discretion, or direct FHIR exchange applies.
NCPDP SCRIPT v2023011
SCRIPT is the core U.S. e-prescribing standard and includes transactions for electronic prior authorization and medication history. Version 2023011 adds required ePA transactions and other prescribing enhancements. Pharmacy ePA follows a distinct NCPDP transaction path from medical-service prior authorization. Buyers must confirm supported SCRIPT versions, network participants, attachments, renewals, and transition readiness.
Operating domains
Timeliness and access to care
Risk that authorization requirements, incomplete requests, review queues, handoffs, or unclear decisions delay or prevent clinically appropriate care beyond required or operationally acceptable timeframes.
Interoperability and transaction reliability
Risk that FHIR, X12, NCPDP, portal, fax, voice, identity, attachment, or legacy-system handoffs fail, lose meaning, duplicate work, or leave no reliable status and audit record.
Transparency, metrics, and comparability
Risk that authorization counts, approval rates, denial rates, appeal outcomes, response times, and automation claims use incompatible populations, definitions, periods, or denominators and therefore mislead buyers or the public.
Evidence and comparison limits
Official provider documentation can establish product positioning. Provider confirmation can clarify package or availability. Independent observation requires a disclosed scenario, environment, date, inputs, and reproducible result. None of those sources alone establishes buyer-specific legal, clinical, regulatory, quality, or operational fitness.
Buyer questions
- What exact outcome and evidence should authorization status tracking produce?
- Which source, version, and customer facts govern the workflow?
- Which decisions remain human and who is accountable for them?
- What is native, configured, integrated, service-delivered, or planned?
- How does a changed source affect open and historical records?
Recent changes
Seven additional DMEPOS codes enter nationwide required prior authorization — DME suppliers and patient-access teams need code-level, date-specific requirement discovery and must also track supplier exemption status.
R1 launches Phare OS-powered prior authorization — Enterprise buyers need a comparison model for combined software and managed operations rather than treating all provider-side products as equivalent automation tools.
Availity and Onyx launch a joint CMS-0057 platform — Health plans can source infrastructure and network reach together, but must still validate component ownership, conformance, production participation, and update responsibilities.